Toleranzia AB
A dissolved biotech company that developed therapies for autoimmune orphan diseases.
TOL | ST
Overview
Corporate Details
- ISIN(s):
- SE0007438577 (+1 more)
- LEI:
- 529900ARVN1D3A4CHI81
- Country:
- Sweden
- Address:
- Arvid Wallgrens backe 20, 413 46 Göteborg
- Website:
- https://www.toleranzia.se/
Description
Toleranzia AB was a biotechnology company focused on developing treatments for autoimmune orphan diseases. The company's technology platform was designed to induce immune tolerance, addressing the underlying cause of the disease. Its primary drug candidate, TOL2, was in development for the treatment of the rare neuromuscular disorder myasthenia gravis. In August 2025, Toleranzia AB was dissolved following a merger with Flerie AB. All of Toleranzia's assets, liabilities, and operations were transferred to Flerie and are now continued within a new subsidiary, Bonsai Biotherapeutics AB.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| No filings match the current criteria. | |||||
Automate Your Workflow. Get a real-time feed of all Toleranzia AB filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Toleranzia AB
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Toleranzia AB via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2025-04-04 | Thomas Eldered | Other | Sell | 12,000,000 | 5,100,000.00 SEK |
| 2025-04-03 | Thomas Eldered | Other | Sell | 23,764,705 | 10,099,999.62 SEK |
Peer Companies
